The charts are presently flashing some powerful signals on the likely course of the world economy.
Closed padlock denotes paid-subscriber only content. Click here to find out more.
Last week I looked at £-cost averaging as a strategy for dealing with bombed out stock markets. Another approach when stock markets are falling is to stay out until there is a clear buy signal.
|
This is a superb business and subscribers should take the opportunity to buy the shares.
|
If you want a company caught in the eye of the storm of falling property prices, sliding cash flow and hefty debt, then this pub group is a good candidate.
|
A feature of the UK stock market in 2008 has been the total collapse of share prices for companies exposed to the UK housing market.
|
More articles from Share Tips
This company is growing like no tomorrow and showing no sign of stopping.
Savills will be all the stronger in the next bull cycle.
I am increasingly coming to the view that UK investors should consider buying into high quality smaller US growth stocks. The US has a number of high quality quoted companies that dominate in niche markets.
In my growing enthusiasm for the healthcare sector I have been sceptical of the ability of the drug majors to prove exciting investments. However a closer look at one drug giant is making me think that I have been too hasty.
In a recent issue I wrote about the Coppock indicator, a useful way of spotting when a new bull market has began. So far we have not had any buy signal.
The conventional wisdom is that the inflation numbers will become worse, say reaching five per cent, before the rate starts to fall. My guess is that once we do have falling inflation numbers the pressure for lower interest rates is going to become irresistible. Once rates start to fall they could drop a long way.
I said recently that my short positions needed an exit strategy and suggested three possible options.
This company has turned into a spectacular growth story, with group turnover in the second quarter up 50 per cent to $48.7m.
In line with my general bullishness about the health care sector I think now would be a good time to add to holdings of this biopharmaceutical company.
Sponsored Links
Editorial Archives
Can't find what you're looking for?
Find more articles in our Editorial Archives
